FranΓ§aisπ See the interactive version (live chart) β
For Avantor, we replayed every analyst price target of the past 12 months and measured the real outcome: 27% were profitable, average return -1% (159 calls). At 3 months: -1% average return (37% profitable). The higher the %, the more often analysts were right on this stock.
Their past track record on this stock (targets replayed against real prices) β not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Barclays | 29 | 24% | -8% |
| Raymond James | 22 | 41% | +8% |
| Morgan Stanley | 16 | 44% | +4% |
| Baird | 15 | 20% | -11% |
| Wells Fargo | 12 | 17% | -9% |
Is Avantor overvalued, and is it a good time to buy Avantor right now? If you're wondering, here's a recap to make up your own mind: Avantor's valuation vs its sector median, to weigh alongside analyst reliability (above) and past performance. Educational information, not buy advice.
The P/E (price Γ· earnings per share) = how many years of earnings you pay for the stock. The higher it is, the more growth the market expects β but the pricier the stock, so more vulnerable if growth disappoints. The forward P/E uses next year's expected earnings: lower than the current P/E = rising expected earnings. We compare it to the sector median to see whether the stock is expensive relative to its peers.
| Metric | Avantor | Sector median (Health Care) |
|---|---|---|
| P/E | 33.4 | 29.4 |
| Forward P/E | 18.8 | 17.9 |
| Net margin | 5% | 13% |
π Avantor is valued in line with its sector (33.4 vs 29.4).
π P/E, PEG, marginβ¦: see the glossary
The analyst consensus on Avantor (AVTR) is "Hold" (4 bullish, 6 bearish calls over 12 months). This is not advice: historically, 27% of their targets on this stock turned out profitable over 1 year.
The median 12-month price target is $16.00 (-4% vs $16.68), ranging from $11.00 to $18.00 (8 analysts).
Over 1 year, 27% of analyst targets on Avantor were profitable, for an average return of -1% (across 159 timestamped calls). This is JPI Invest's accuracy metric.
Analysts target a median of $16.00 within 12 months, i.e. -4% vs the current price. The most bullish targets $18.00, the most cautious $11.00.
Note: analyst targets are 12-month (median $16.00, -4%), NOT 2030. No reliable 5-10 year price forecast exists (Β« 2030 prediction Β» models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (27%), and the stock's past trajectory.
Its P/E is 33.4, forward P/E 18.8. A forward P/E lower than the current P/E means earnings are expected to grow.
π See the full interactive analysis of Avantor β
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best β on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
Explore JPI Invest for free β How it works: the method β
β οΈ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.